From Cholesterol to Total Risk: Nature’s Answer to What Medicine Has Missed
Published on: 07/09/2025
“Most heart attacks happen with normal cholesterol. Icosapent Ethyl (EPA) goes beyond LDL, reducing cardiovascular events, stabilizing plaque, and addressing total risk where statins alone fall short.”
icosapent ethylvascepaEPAReduce-IT trial outcomesCardiovascular Risk ReductionResidual Cardiovascular RiskChronic Kidney Disease(CKD) and Cardiovascular (CV) riskNumber Needed to Treat(NNT)EVAPORATE TRIALInflammation and AtherosclerosisPlaque stabilization TherapyOmega 3 fatty acids in cardiologyInsulin resistance and cardiovascular riskClinical inertia in cardiology

